Search for: "C.D.2" Results 981 - 1000 of 1,458
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 Nov 2017, 4:23 pm by Jeff Kern and Kate Ross*
Id. at 2. [7] Urska Velikonja, Behind the Annual SEC Enforcement Report: 2017 and Beyond 1 (November 19, 2017), available here. [8] Id. at 2, 4-6. [9] Id. at 5, n. 6. [10] See id. at 5, n. 7. [11] See id. at 4. [12] S.E.C. [read post]
1 Dec 2017, 2:55 pm by Jeff Kern and Kate Ross*
Id. at 2. [7] Urska Velikonja, Behind the Annual SEC Enforcement Report: 2017 and Beyond 1 (November 19, 2017), available here. [8] Id. at 2, 4-6. [9] Id. at 5, n. 6. [10] See id. at 5, n. 7. [11] See id. at 4. [12] S.E.C. [read post]
21 Oct 2011, 2:00 am by Stefanie Levine
Patent No. 6,794,410 entitled USE OF (Z) -2-CYANO-3-HYDROXY- BUT-2-ENOIC ACID-(4-TRIFLUOROMETHYLPHENYL) -AMIDE FOR TREATING MULTIPLE SCLEROSIS and owned by Aventis Pharmaceuticals. [read post]
21 Oct 2011, 2:00 am by Stefanie Levine
Patent No. 6,794,410 entitled USE OF (Z) -2-CYANO-3-HYDROXY- BUT-2-ENOIC ACID-(4-TRIFLUOROMETHYLPHENYL) -AMIDE FOR TREATING MULTIPLE SCLEROSIS and owned by Aventis Pharmaceuticals. [read post]
28 May 2020, 4:51 pm by Adam Rosenthal and Robert Foster
This does not apply to drivers who qualify for either of the short-haul exceptions in  395.1(e)(1) or (2). [read post]
4 Nov 2021, 5:37 am by Eugene Volokh
Let's turn now to how pseudonymity may be concretely harmful, and how open disclosure of party names may be valuable. [2.] [read post]